Fifth Third Wealth Advisors LLC Has $1.42 Million Stake in Gilead Sciences, Inc. $GILD

Fifth Third Wealth Advisors LLC trimmed its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.0% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,763 shares of the biopharmaceutical company’s stock after selling 536 shares during the period. Fifth Third Wealth Advisors LLC’s holdings in Gilead Sciences were worth $1,415,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Richardson Financial Services Inc. acquired a new stake in shares of Gilead Sciences in the second quarter valued at approximately $169,000. Conning Inc. raised its position in shares of Gilead Sciences by 1.9% in the second quarter. Conning Inc. now owns 318,581 shares of the biopharmaceutical company’s stock valued at $35,321,000 after buying an additional 5,854 shares in the last quarter. Brucke Financial Inc. raised its position in Gilead Sciences by 57.8% during the second quarter. Brucke Financial Inc. now owns 3,611 shares of the biopharmaceutical company’s stock valued at $400,000 after purchasing an additional 1,322 shares in the last quarter. PDS Planning Inc raised its position in Gilead Sciences by 11.4% during the second quarter. PDS Planning Inc now owns 5,790 shares of the biopharmaceutical company’s stock valued at $642,000 after purchasing an additional 592 shares in the last quarter. Finally, Blue Trust Inc. raised its position in Gilead Sciences by 12.5% during the second quarter. Blue Trust Inc. now owns 4,497 shares of the biopharmaceutical company’s stock valued at $499,000 after purchasing an additional 499 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Stock Up 0.4%

Shares of NASDAQ:GILD opened at $117.18 on Friday. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. Gilead Sciences, Inc. has a 52-week low of $84.17 and a 52-week high of $121.83. The company has a market capitalization of $145.40 billion, a PE ratio of 23.34, a price-to-earnings-growth ratio of 0.80 and a beta of 0.34. The company has a fifty day moving average of $114.65 and a 200-day moving average of $110.26.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company had revenue of $7.08 billion for the quarter, compared to analysts’ expectations of $6.95 billion. During the same quarter in the previous year, the firm posted $2.01 earnings per share. Gilead Sciences’s revenue for the quarter was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, equities analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were paid a $0.79 dividend. The ex-dividend date of this dividend was Monday, September 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.7%. Gilead Sciences’s payout ratio is currently 62.95%.

Analyst Ratings Changes

Several research analysts have commented on GILD shares. Cantor Fitzgerald boosted their price objective on shares of Gilead Sciences from $129.00 to $135.00 and gave the company an “overweight” rating in a research report on Thursday. UBS Group boosted their price objective on shares of Gilead Sciences from $108.00 to $112.00 and gave the company a “neutral” rating in a research report on Friday, August 8th. Dbs Bank upgraded shares of Gilead Sciences to a “moderate buy” rating in a research report on Friday, September 5th. Citigroup boosted their price objective on shares of Gilead Sciences from $125.00 to $135.00 and gave the company a “buy” rating in a research report on Wednesday. Finally, Daiwa America upgraded shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, August 19th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $118.08.

Insider Buying and Selling

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction on Monday, September 29th. The shares were sold at an average price of $111.66, for a total transaction of $1,116,600.00. Following the sale, the chief executive officer owned 591,203 shares of the company’s stock, valued at approximately $66,013,726.98. This represents a 1.66% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction on Monday, September 15th. The shares were sold at an average price of $113.57, for a total transaction of $283,925.00. Following the sale, the chief financial officer directly owned 159,555 shares in the company, valued at $18,120,661.35. This trade represents a 1.54% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 82,000 shares of company stock valued at $9,402,130 over the last 90 days. 0.27% of the stock is owned by insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.